25 Leading Nuclear Medicine Companies Shaping Innovation and Market Growth to 2030

Discover the top 25 companies driving innovation in the nuclear medicine market. This in-depth analysis explores competitive advantages, transformative trends, and key players poised to influence diagnostic imaging, cancer care, and targeted radionuclide therapies through 2030. Access the comprehensive market research report here for further insights.

Spotlights on the Industry's Top Nuclear Medicine Companies

The nuclear medicine market is evolving rapidly as advances in radiopharmaceutical development, molecular imaging, and targeted radionuclide therapy expand the role of nuclear medicine in modern healthcare. Innovations in positron emission tomography (PET), single-photon emission computed tomography (SPECT), and therapeutic radioisotopes such as lutetium-177 and yttrium-90 are supporting more precise disease diagnosis and treatment, particularly in oncology, cardiology, and neurology. Increasing demand for personalized medicine, investments in radioisotope production, and improvements in radiopharmaceutical manufacturing and distribution are strengthening competition among pharmaceutical companies, imaging technology providers, and specialized isotope manufacturers. These developments are creating opportunities for companies with capabilities spanning the radiopharmaceutical value chain, from isotope production and drug development to imaging systems and clinical applications.

1. Novartis AG

Novartis AG is a major pharmaceutical company with a significant presence in nuclear medicine through its radioligand therapy portfolio. Its Pluvicto (lutetium Lu 177 vipivotide tetraxetan) is used to treat eligible patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer, while Lutathera (lutetium Lu 177 dotatate) targets somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors. These therapies combine molecular targeting with radioactive isotopes to deliver radiation to cancer cells. Novartis's expertise in oncology, clinical development, and radioligand therapy manufacturing positions it as an important participant in the therapeutic nuclear medicine segment.

2. Lantheus Holdings, Inc.

Lantheus Holdings, Inc. develops and commercializes diagnostic imaging agents and radiopharmaceutical products used in disease detection and clinical decision-making. Its portfolio includes Pylarify (piflufolastat F 18), a PET imaging agent used to detect PSMA-positive prostate cancer, and Definity, an ultrasound-enhancing agent. The company also participates in the broader radiopharmaceutical ecosystem through its imaging and therapeutic development activities. Its experience in molecular imaging, commercialization, and nuclear medicine distribution supports its role in advancing diagnostic precision and expanding the clinical use of radiopharmaceuticals, particularly in oncology and other specialized imaging applications.

3. GE HealthCare

GE HealthCare is a global medical technology company offering diagnostic imaging systems, molecular imaging solutions, and related healthcare technologies. Its nuclear medicine portfolio includes PET and SPECT imaging systems that help clinicians assess cancer, cardiac conditions, neurological disorders, and other diseases. The company also provides cyclotron and radiopharmaceutical-related solutions through its broader molecular imaging business, supporting the production and use of medical isotopes. By combining imaging hardware, digital technologies, workflow solutions, and service capabilities, GE HealthCare helps healthcare providers improve diagnostic efficiency and integrate nuclear medicine into clinical care.

4. Curium

Curium is a radiopharmaceutical company specializing in nuclear medicine products for diagnostic imaging and therapeutic applications. Its portfolio includes SPECT radiopharmaceuticals and PET imaging agents used in a range of clinical procedures, including bone, cardiac, and oncology imaging. The company has an established radiopharmaceutical manufacturing and distribution network designed to meet the time-sensitive requirements of nuclear medicine, where radioactive decay makes reliable delivery essential. Curium's expertise in isotope-based products, manufacturing infrastructure, and hospital supply chains supports its position in the global nuclear medicine market as demand for molecular imaging and targeted therapies expands.

5. Telix Pharmaceuticals Limited

Telix Pharmaceuticals Limited is a biopharmaceutical company focused on the development and commercialization of radiopharmaceutical products for cancer imaging and treatment. Its portfolio includes Illuccix, a kit for the preparation of gallium-68 gozetotide used in PSMA PET imaging, and other investigational or commercial radiopharmaceutical programs targeting cancer and other diseases. Telix's development strategy emphasizes precision medicine through molecularly targeted imaging and therapy, including programs involving prostate cancer and renal cancer. Its specialized research capabilities and focus on theranostics—the combination of diagnostic imaging and targeted treatment—support its relevance to the evolving nuclear medicine industry.

6. Siemens Healthineers

Siemens Healthineers is a medical technology company providing advanced imaging systems and diagnostic solutions for hospitals and imaging centers worldwide. Its nuclear medicine capabilities include PET/CT and SPECT/CT systems that combine functional imaging with anatomical information to support disease diagnosis, staging, and treatment monitoring. The company also develops molecular imaging technologies, image reconstruction tools, and workflow solutions that help healthcare providers improve image quality and operational efficiency. Its global service infrastructure and established presence in diagnostic imaging make Siemens Healthineers an important technology provider in the nuclear medicine market, particularly as demand for precision diagnostics increases.

7. China Isotope & Radiation Corporation

China Isotope & Radiation Corporation (CIRC) operates in China's isotope and radiation technology industry, with activities spanning radiopharmaceuticals, radioactive sources, and related medical applications. Its nuclear medicine business supports the use of radioisotopes in diagnostic imaging and therapeutic procedures, serving healthcare providers and other customers in relevant markets. The company benefits from its position within China's broader nuclear technology ecosystem and its involvement in isotope-related production and supply chains. Its role is relevant to the expansion of domestic radiopharmaceutical capabilities, the availability of medical isotopes, and the development of nuclear medicine services across China.

8. Bayer AG

Bayer AG participates in the nuclear medicine market through Xofigo (radium Ra 223 dichloride), a radiopharmaceutical used to treat certain patients with castration-resistant prostate cancer and symptomatic bone metastases without known visceral metastatic disease. Xofigo uses an alpha-emitting radionuclide to deliver localized radiation to areas of increased bone turnover associated with cancer. Bayer's oncology expertise and established pharmaceutical development and commercialization capabilities support its position in targeted radionuclide therapy. Its involvement illustrates the role of pharmaceutical companies in developing specialized radioactive medicines for patients who may benefit from treatment approaches beyond conventional systemic therapies.

9. Bracco Imaging S.p.A.

Bracco Imaging S.p.A. is a diagnostic imaging company with capabilities spanning contrast agents, imaging technologies, and nuclear medicine products. Its PET imaging portfolio includes products and solutions that support molecular imaging, while its broader business serves healthcare professionals across multiple diagnostic modalities. Bracco's expertise in imaging agents, pharmaceutical manufacturing, and diagnostic workflows contributes to its relevance in the nuclear medicine ecosystem. As PET imaging becomes increasingly important for oncology and other clinical applications, the company's established presence in diagnostic imaging and focus on imaging innovation support its participation in the development of advanced diagnostic solutions.

10. Cardinal Health

Cardinal Health is a healthcare services and products company with an important role in the US radiopharmaceutical supply chain. Through its nuclear pharmacy operations, the company prepares, dispenses, and distributes radiopharmaceuticals used in diagnostic imaging and certain therapeutic procedures. Its services support hospitals, clinics, and imaging centers that require timely access to short-lived radioactive products. Cardinal Health's pharmacy infrastructure, logistics capabilities, and established relationships with healthcare providers help address the specialized handling, regulatory compliance, and delivery requirements associated with nuclear medicine. These capabilities make the company an important participant in radiopharmaceutical distribution and clinical access.

11. Jubilant Pharmova Limited

Jubilant Pharmova Limited participates in the nuclear medicine industry through its radiopharmaceutical business, which includes the development, manufacturing, and distribution of products used in diagnostic imaging and therapeutic applications. Its radiopharmacy operations serve healthcare providers that rely on reliable access to radioactive diagnostic agents, while its broader pharmaceutical capabilities contribute to specialized product manufacturing. The company's experience in regulated pharmaceutical production and radiopharmaceutical supply chains supports its relevance to the market. Its role is particularly associated with meeting clinical demand for nuclear medicine products and supporting the delivery of time-sensitive radiopharmaceuticals to healthcare facilities.

12. Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company with a historical connection to nuclear medicine through its former subsidiary Avid Radiopharmaceuticals, which developed imaging agents for neurological research and disease assessment. Avid's florbetapir F 18 technology, marketed as Amyvid, was developed for PET imaging of beta-amyloid neuritic plaques in the brain. Eli Lilly subsequently divested Avid Radiopharmaceuticals, so its historical involvement should be distinguished from current direct market participation. Its connection to the development of molecular imaging agents illustrates how pharmaceutical research has contributed to the use of radiopharmaceuticals in neurological disease assessment and biomarker-based diagnostics.

13. BWXT Medical Ltd.

BWXT Medical Ltd. specializes in the production of medical radioisotopes, radiopharmaceuticals, and related products used in diagnostic imaging and therapeutic applications. Its capabilities include isotope processing and manufacturing solutions that support the supply of specialized materials to healthcare and life sciences customers. The company also provides services related to the production of medical isotopes and radiopharmaceutical ingredients for research and clinical use. Its expertise in nuclear technology, isotope production, and regulated manufacturing positions it within the upstream and manufacturing segments of the nuclear medicine value chain, where dependable supply is essential for expanding diagnostic and therapeutic applications.

14. NTP Radioisotopes SOC Ltd. (a subsidiary of the South African Nuclear Energy Corporation)

NTP Radioisotopes SOC Ltd. is a South African supplier of medical radioisotopes and radiopharmaceutical products for nuclear medicine applications. As a subsidiary of the South African Nuclear Energy Corporation, it operates within the country's nuclear science and technology infrastructure. The company has been associated with the production and supply of isotopes used in diagnostic imaging and cancer treatment, including molybdenum-99 and other medically relevant radioisotopes. Its production expertise and international supply activities contribute to the availability of nuclear medicine materials for healthcare providers, making it relevant to efforts to diversify and strengthen global medical isotope supply chains.

15. Eckert & Ziegler

Eckert & Ziegler is a specialist in isotope technology and radiopharmaceutical components, supplying radioactive materials and services for medical, scientific, and industrial applications. Its medical business includes radioisotopes and products used in radiopharmaceutical development, nuclear medicine, and targeted radionuclide therapies. The company also offers isotope-related manufacturing and processing capabilities that support the development and production of radiopharmaceuticals. Its experience in handling radioactive materials and serving regulated healthcare markets makes it an important supplier across the nuclear medicine value chain, particularly as demand grows for therapeutic isotopes and specialized radiopharmaceutical manufacturing services.

16. Isotope JSC

Isotope JSC is a Russian organization associated with the distribution and supply of radioisotopes and isotope-based products, including materials used in medical and scientific applications. Its activities are relevant to nuclear medicine through the supply chain for diagnostic and therapeutic radioisotopes and related products. The company's role should be understood in the context of isotope distribution and market access rather than assumed to represent a globally diversified radiopharmaceutical drug-development business. Its market relevance depends on the availability of specific products, applicable regulatory requirements, and its relationships with domestic and international customers across the medical isotope sector.

17. PD Radiopharma Inc.

PD Radiopharma Inc. is a Canadian radiopharmaceutical company involved in the supply and distribution of products used in nuclear medicine. Its business supports diagnostic imaging and therapeutic procedures through radiopharmaceutical products and related services for healthcare providers. The company operates in a specialized market where product quality, radiation safety, regulatory compliance, and reliable delivery are central to clinical use. Its position in the Canadian nuclear medicine ecosystem contributes to access to radiopharmaceuticals for hospitals and imaging facilities, while its specialized focus supports the broader adoption of isotope-based diagnostic and treatment technologies.

18. ITM Isotope Technologies Munich SE

ITM Isotope Technologies Munich SE is a radiopharmaceutical biotechnology company focused on the development, production, and supply of medical radioisotopes and targeted radiopharmaceuticals, particularly for cancer treatment. Its portfolio includes programs based on lutetium-177 and other therapeutic radionuclides, supported by capabilities in isotope production, radiopharmaceutical development, and contract manufacturing. ITM's integrated approach addresses a key challenge in nuclear medicine: ensuring consistent access to high-quality therapeutic isotopes and finished products. Its focus on targeted radionuclide therapy and supply-chain development positions it as a relevant participant in the expansion of precision oncology and theranostic medicine.

19. Narodowe Centrum Badan Jadrowych – Osrodek Radioizotopów POLATOM

Narodowe Centrum Badan Jadrowych – Osrodek Radioizotopów POLATOM, commonly known as NCBJ POLATOM, is a Polish producer of radioisotopes and radiopharmaceuticals for medical and scientific applications. Its activities include products used in diagnostic nuclear medicine and selected therapeutic procedures, as well as isotope-related research and development. The organization contributes to the European medical isotope supply chain through its expertise in radioisotope production and radiopharmaceutical preparation. Its role is relevant to hospitals and nuclear medicine departments that require reliable access to specialized radioactive products for imaging, disease evaluation, and treatment.

20. ANSTO

The Australian Nuclear Science and Technology Organisation (ANSTO) is Australia's national nuclear science agency and an important participant in the medical isotope sector. Through its nuclear science infrastructure and radiopharmaceutical capabilities, ANSTO produces and supplies radioisotopes used in diagnostic imaging and therapeutic applications. Its activities include medical isotope production and research supporting nuclear medicine, with molybdenum-99 being particularly important for the supply of technetium-99m used in SPECT procedures. ANSTO's research expertise and production infrastructure contribute to global isotope supply resilience and the continued availability of essential radiopharmaceutical materials for clinical diagnosis and treatment.

21. SHINE Technologies, LLC

SHINE Technologies, LLC is a US-based technology company developing nuclear fusion-related systems and isotope production capabilities, with a significant focus on medical isotopes. Its work includes molybdenum-99 production technologies intended to support the supply of technetium-99m, a widely used isotope in diagnostic nuclear medicine. The company is also developing capabilities related to other medical and industrial isotopes. By pursuing alternative production approaches and investing in isotope manufacturing infrastructure, SHINE addresses the need for reliable, scalable, and diversified sources of medical radioisotopes, supporting the long-term resilience of the nuclear medicine supply chain.

22. Isotopia Molecular Imaging Ltd.

Isotopia Molecular Imaging Ltd. is an Israel-based radiopharmaceutical company focused on the development and supply of products for molecular imaging and targeted radionuclide therapy. Its activities include radiopharmaceuticals based on medical isotopes used in diagnostic and therapeutic applications, with a focus on expanding access to specialized nuclear medicine products. The company's position in the market reflects the growing importance of theranostics, where molecular imaging helps identify appropriate patients and guide targeted treatment. Its radiopharmaceutical development and manufacturing capabilities support the expansion of precision oncology and other applications requiring isotope-based diagnostic and therapeutic approaches.

23. Institute of Isotopes

The Institute of Isotopes is a Hungarian research and production organization involved in the development and manufacture of radioisotopes and radiopharmaceutical products. Its activities support medical and scientific applications, including nuclear medicine diagnostics and therapeutic research. The institute contributes to isotope production, radiopharmaceutical development, and related technical expertise within the European nuclear science ecosystem. Its capabilities are relevant to the supply of specialized radioactive materials and the development of new isotope-based applications. As healthcare systems expand molecular imaging and targeted radionuclide therapies, organizations with established isotope research and production expertise remain important to the industry's technical and supply-chain infrastructure.

24. Global Medical Solutions

Global Medical Solutions operates in the medical isotope and radiopharmaceutical supply sector, supporting healthcare providers that require access to nuclear medicine products. Its market relevance is associated with the supply-chain infrastructure needed to distribute radiopharmaceuticals and related products to clinical facilities. In nuclear medicine, reliable logistics, product handling, and coordination with healthcare providers are particularly important because radioactive materials have limited usable lifetimes and are subject to strict safety and regulatory requirements. The company's role should be assessed against its specific regional operations and product portfolio, particularly when evaluating its contribution to diagnostic imaging and therapeutic radiopharmaceutical access.

25. Isotex Diagnostics

Isotex Diagnostics is identified as a participant in the nuclear medicine and radiopharmaceutical sector; however, its specific product portfolio, manufacturing capabilities, and geographic market presence should be independently verified before publication. Companies operating in this segment may contribute through isotope supply, radiopharmaceutical distribution, diagnostic products, or related services, but these activities should not be attributed to Isotex Diagnostics without reliable supporting evidence. Confirming the company's legal identity, official website, current business activities, and relevance to PET, SPECT, or therapeutic radioisotopes will help ensure the accuracy of its market positioning in this company landscape.